Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verona Pharma Plc ADR (NQ: VRNA )

22.48 -0.18 (-0.79%)
Streaming Delayed Price Updated: 3:22 PM EDT, Aug 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 602,103
Open 22.78
Bid (Size) 22.46 (1)
Ask (Size) 22.50 (2)
Prev. Close 22.66
Today's Range 22.15 - 23.31
52wk Range 11.39 - 23.72
Shares Outstanding 480,291,822
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top 3 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+19.51%
+19.51%
1 Month
+44.94%
+44.94%
3 Month
+47.70%
+47.70%
6 Month
+22.51%
+22.51%
1 Year
+4.80%
+4.80%

More News

Read More
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Via Benzinga
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Earnings Scheduled For February 29, 2024
Via Benzinga
Earnings Preview For Verona Pharma
Via Benzinga
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
Via Investor's Business Daily
VRNA Stock Earnings: Verona Pharma Misses EPS for Q1 2024
Via InvestorPlace
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2024
Via The Motley Fool
Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves
Via Benzinga
Expert Ratings for Verona Pharma
Via Benzinga
Earnings Scheduled For August 3, 2023
Via Benzinga
4 Analysts Have This to Say About Verona Pharma
Via Benzinga
Earnings Preview For Verona Pharma
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
Via Talk Markets
Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Earnings Scheduled For November 2, 2023
Via Benzinga
Earnings Scheduled For May 9, 2023
Via Benzinga
7 Biotech Stocks That Could Be the Next Big Thing
Via InvestorPlace
PDS Biotechnology, Pulmonx, Tesla And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Why These 7 Healthcare Stocks Could Soar in 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.